Benzinga | Apr 7, 2021 07:50AM EDT

Mizuho Downgrades FibroGen to Neutral, Announces $29 Price Target

Mizuho analyst Difei Yang downgrades FibroGen (NASDAQ:FGEN) from Buy to Neutral and announces $29 price target.